Clinical Trials Logo

Neoplasms, Bladder clinical trials

View clinical trials related to Neoplasms, Bladder.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05072600 Recruiting - Bladder Cancer Clinical Trials

Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer

Start date: December 7, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase II, single-arm, study of pembrolizumab as maintenance therapy in muscle-invasive bladder cancer (MIBC) participants who have received maximum TURBT and tri-modality treatment (TMT) and achieved CR. All participants will receive pembrolizumab monotherapy per 21 days no longer than 17 cycles until disease progression or death.

NCT ID: NCT04892342 Recruiting - Neoplasms, Breast Clinical Trials

Study of ESG401 in Adults With Solid Tumors

Start date: September 14, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective in Phase I is to evaluate the safety and tolerability of ESG401 as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial cancer. In Phase II, the primary objective is to evaluate the safety and efficacy of ESG401 administered in 21-day treatment cycles at a dose selected in Phase I. Tumor types in the study will include: cervical, colorectal, endometrial, ovarian, esophageal, gastric adenocarcinoma, glioblastoma multiforme, head and neck cancers- squamous cell, hepatocellular, prostate, non-small-cell lung cancer, pancreatic, renal cell, small-cell lung cancer, non-triple negative breast cancer (non-TNBC), triple-negative breast cancer (TNBC) and metastatic urothelial cancer (mUC).